- Home
- ACRS
as 07-26-2024 4:00pm EST
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | WAYNE |
| Market Cap: | 94.1M | IPO Year: | 2015 |
| Target Price: | $11.50 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.59 - $10.15 | Next Earning Date: | 08-05-2024 |
| Revenue: | $31,119,000 | Revenue Growth: | 0.95% |
| Revenue Growth (this year): | -74.26% | Revenue Growth (next year): | -1.88% |
Stock Insider Trading Activity of Aclaris Therapeutics Inc. (ACRS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | ACRS | 10% Owner | Jul 2 '24 | Buy | $1.15 | 123,017 | $141,334.23 | 13,447,969 | SEC Form 4 |
| Leonard Braden Michael | ACRS | 10% Owner | Jul 2 '24 | Buy | $1.16 | 143,288 | $166,070.79 | 13,324,952 | SEC Form 4 |
| Leonard Braden Michael | ACRS | 10% Owner | Jul 2 '24 | Buy | $1.14 | 86,092 | $98,489.25 | 13,181,664 | SEC Form 4 |
| Leonard Braden Michael | ACRS | 10% Owner | Jun 27 '24 | Buy | $1.14 | 107,434 | $122,184.69 | 13,095,572 | SEC Form 4 |
| Leonard Braden Michael | ACRS | 10% Owner | Jun 27 '24 | Buy | $1.13 | 400,000 | $452,000.00 | 12,988,134 | SEC Form 4 |
| Leonard Braden Michael | ACRS | 10% Owner | Jun 27 '24 | Buy | $1.12 | 801,000 | $896,559.30 | 12,588,134 | SEC Form 4 |
| Leonard Braden Michael | ACRS | 10% Owner | Jun 27 '24 | Buy | $1.15 | 235,000 | $271,331.00 | 11,787,134 | SEC Form 4 |
| Leonard Braden Michael | ACRS | 10% Owner | Jun 14 '24 | Buy | $1.13 | 50,000 | $56,505.00 | 11,552,134 | SEC Form 4 |
| Leonard Braden Michael | ACRS | 10% Owner | Jun 14 '24 | Buy | $1.13 | 150,000 | $169,500.00 | 11,502,134 | SEC Form 4 |
| Leonard Braden Michael | ACRS | 10% Owner | Jun 14 '24 | Buy | $1.17 | 345,000 | $402,201.00 | 11,352,134 | SEC Form 4 |
| Leonard Braden Michael | ACRS | 10% Owner | Jun 11 '24 | Buy | $1.08 | 1,000,000 | $1,080,000.00 | 10,395,934 | SEC Form 4 |
| Leonard Braden Michael | ACRS | 10% Owner | Jun 11 '24 | Buy | $1.15 | 500,000 | $575,000.00 | 11,007,134 | SEC Form 4 |
| Leonard Braden Michael | ACRS | 10% Owner | Jun 11 '24 | Buy | $1.14 | 28,621 | $32,756.73 | 10,507,134 | SEC Form 4 |
| Leonard Braden Michael | ACRS | 10% Owner | Jun 11 '24 | Buy | $1.14 | 82,579 | $94,140.06 | 10,478,513 | SEC Form 4 |
| Powell Andrew Kenneth William | ACRS | Director | Mar 1 '24 | Buy | $1.23 | 8,500 | $10,455.00 | 22,863 | SEC Form 4 |
| Powell Andrew Kenneth William | ACRS | Director | Mar 1 '24 | Buy | $1.25 | 6,000 | $7,500.00 | 28,863 | SEC Form 4 |
Latest Aclaris Therapeutics Inc. News
ACRS Breaking Stock News: Dive into ACRS Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
MT Newswires
10 days ago
Aclaris Therapeutics Sells Olumiant Royalties, Milestone Payments From Eli Lilly
GlobeNewswire
10 days ago
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Zacks
17 days ago
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
MT Newswires
21 days ago
Aclaris Therapeutics Insider Bought Shares Worth $405,894, According to a Recent SEC Filing
MT Newswires
25 days ago
Aclaris Therapeutics Insider Bought Shares Worth $1,742,075, According to a Recent SEC Filing
GlobeNewswire
2 months ago
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Simply Wall St.
3 months ago
Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates
Compare ACRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACRS Aclaris Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.